非血縁者間末梢血幹細胞採取(<特集>ドナーアフェレシスの現状と展開)

概要

論文の詳細を見る
Allogeneic peripheral blood stem cell transplantation (PBSCT) as well as allogeneic bone marrow transplantation (BMT) is a curative treatment strategy for patients with hematopoietic disorders. PBSCT is associated with more rapid hematopoietic recovery than BMT. Although PBSC harvest is feasible without the risk of anesthesia or invasive multiple bone marrow aspirations, the other concern is the short-term and long-term safety. In a nation-wide prospective survey of the Japan Society for Hematopoietic Cell Transplantation and other worldwide registry data, PBSC harvest was mostly tolerated as well as BM collection. Since the first unrelated PBSCT in 2011, 4 transplants have been performed. Both patients and donors have more therapeutic options by the use of PBSC for unrelated donor transplantation. However, some problems (work-sharing, apheresis center, management of post-transplantation, cryopreservation, etc.) should be solved.
2012-10-31